MDNA Company Profile and Key Details

Q: Who are the executives of MDNA?

Dr. Fahar Merchant Ph.D.Founder, Chairman, Pres & Chief Executive OfficerMs. Rosemina Merchant B.Sc., M.E.ScFounder, Chief Devel. Officer & DirectorMs. Elizabeth Williams C.A., CPA, CA, CPAChief Financial Officer & Corporation Sec.Dr. Martin Bexon M.D., MBBSActing Chief Medical Officer & Head of Clinical Devel.

NASDAQ : MDNA

Medicenna Therapeutics

$0.16

At Close 4:00 PM

Not Actively Trading

61.37

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Medicenna Therapeutics Corp. (MDNA) stock remained unchanged at $0.16 a share on NASDAQ. The stock opened at $0.20, fluctuating between $0.15 to $0.20 during the session.

Stock Snapshot

0.157

Prev. Close

Market Cap

0.15125

Day Low

-1.7444444444444445

P/E Ratio

-0.09

EPS (TTM)

-0.19

Cash Flow per Share

0.2

Open

Number of Shares

0.1999

Day High

70.02%

Free Float in %

0.34

Book Value

1.26M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 16, 2025	0.20	0.20	0.15	0.16	1.26M
Nov 27, 2023	0.37	0.37	0.34	0.37	52.37K
Nov 24, 2023	0.33	0.34	0.32	0.34	91.44K
Nov 22, 2023	0.31	0.32	0.31	0.31	2.98K
Nov 21, 2023	0.31	0.34	0.31	0.32	28.76K
Nov 20, 2023	0.32	0.34	0.31	0.31	29.05K
Nov 17, 2023	0.36	0.37	0.30	0.32	77.44K
Nov 16, 2023	0.37	0.38	0.36	0.36	132.53K
Nov 15, 2023	0.40	0.40	0.37	0.38	261.2K
Nov 14, 2023	0.39	0.40	0.37	0.37	65.07K
Nov 13, 2023	0.39	0.39	0.34	0.37	36.4K
Nov 10, 2023	0.39	0.44	0.33	0.44	254.84K
Nov 09, 2023	0.35	0.40	0.35	0.39	165.34K
Nov 08, 2023	0.33	0.36	0.30	0.34	283.9K
Nov 07, 2023	0.30	0.35	0.29	0.33	351.42K
Nov 06, 2023	0.28	0.35	0.22	0.32	811.09K
Nov 03, 2023	0.18	0.26	0.18	0.26	248.66K
Nov 02, 2023	0.16	0.19	0.16	0.18	189.01K
Nov 01, 2023	0.20	0.20	0.15	0.16	1.27M
Oct 31, 2023	0.18	0.21	0.17	0.18	452.26K

Contact Details

Toronto, ON M4W 3E2

Canada

https://www.medicenna.com 416 648 5555

About Company

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Stock Peers

REGN

2.14+0.28%

Regeneron Pharmaceuticals, Inc.$759.05 ARGX

2.73+0.39%

argenx SE$706.03 UTHR

5.72001+1.07%

United Therapeutics Corporation$540.02 VRTX

-3.61-0.77%

Vertex Pharmaceuticals Incorporated$462.49 MDGL

2.35+0.53%

Madrigal Pharmaceuticals, Inc.$443.18 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.51+0.47%

Alnylam Pharmaceuticals, Inc.$320.42 PRAX

-1.62-0.53%

Praxis Precision Medicines, Inc.$303.38 KRYS

6.17+2.47%

Krystal Biotech, Inc.$256.33 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

The stock is currently within 5% of its 52-week low $0.15 and $0.20. With a market capitalization of about $0.00, Medicenna Therapeutics Corp. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.77). Key stats such as the average daily volume over the past year has been around 1.26 million shares, in line with its 52-week average. Headquartered in Toronto, ON, Medicenna Therapeutics Corp. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Fahar Merchant, the company employs approximately 16 people and listed since November 13, 2017. Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases.

Valuation Metrics

Medicenna Therapeutics Corp. trades at a P/E ratio of 9.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.47 suggesting the stock is closer to book value. The P/FCF stands at 0.0, also above market averages.

Dividend & Fair Value

Medicenna Therapeutics Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.36. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Medicenna Therapeutics Corp. earnings surprise history is a mixed track record. The quarter that ended November 03, 2023, missed forecasts by 0.0%. The prior quarter beat by 35.14%. Over the last six quarters, Apple has recorded several small beats. These include -14.29% in August 15, 2022.

Financial & Profitability Overview

Over the trailing twelve months, Medicenna Therapeutics has not generated any revenue. Returns are negative, with ROA at -41.59% and ROE at -61.82%.
On valuation metrics, Medicenna Therapeutics trades at a P/E of 9.00, P/S of 0.00 and P/B of 0.47. The current ratio is 9.57 and quick ratio is 9.57.

Quarterly Financial Highlights

For the quarter ended Mar 31, 2025, Medicenna Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $55.00K (margin 0.00%). Operating income was - $21.63M (margin 0.0%). Net income was- $11.81M (EPS - $0.15).
The company ended the quarter with $24.84M in cash and short-term investments, a total debt of $168.00K, and net debt of - $24.67M. Total assets were $28.38M, with equity of $19.10M. Financials further reflected weakness, with operating cash flow of - $16.49M, free cash flow of - $16.53M, and capital expenditures of - $33.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Medicenna Therapeutics Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 14.65%, with price expected at $0.18 by January 30, 2025, within a range of $0.11 to $0.25 3-Month Outlook: Projected rise of 33.76%, reaching $0.21 by January 30, 2024, with a range of $0.17 to $0.25. 1-Year Outlook: Projected gain of 65.61%, with price at $0.26 by November 26, 2024, within a range of $0.00 to $0.00.

Key Takeaways

Medicenna Therapeutics Corp. (NASDAQ:MDNA) shares are down -56.41% year-to-date Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Medicenna Therapeutics Corp. trading at a premium to the broader market with a P/E of 9.0. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $2.50, suggesting 1492.36% upside. Our AI forecast model points to short-term strength (14.65% over two weeks), a medium-term rise (33.76% over three months), and a longer-term gain (65.61% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Medicenna Therapeutics Corp. (MDNA) stock price?

Medicenna Therapeutics Corp. (NASDAQ: MDNA) stock price is $0.16 in the last trading session. During the trading session, MDNA stock reached the peak price of $0.20 while $0.15 was the lowest point it dropped to. The percentage change in MDNA stock occurred in the recent session was 0% while the dollar amount for the price change in MDNA stock was $0.00.

MDNA's industry and sector of operation?

The NASDAQ listed MDNA is part of Biotechnology industry that operates in the broader Healthcare sector. Medicenna Therapeutics Corp. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MDNA?

Dr. Fahar Merchant Ph.D.
Founder, Chairman, Pres & Chief Executive Officer
Ms. Rosemina Merchant B.Sc., M.E.Sc
Founder, Chief Devel. Officer & Director
Ms. Elizabeth Williams C.A., CPA, CA, CPA
Chief Financial Officer & Corporation Sec.
Dr. Martin Bexon M.D., MBBS
Acting Chief Medical Officer & Head of Clinical Devel.

How MDNA did perform over past 52-week?

MDNA's closing price is 3.8% higher than its 52-week low of $0.15 where as its distance from 52-week high of $0.20 is -21.46%.

How many employees does MDNA have?

Number of MDNA employees currently stands at 16.

Link for MDNA official website?

Official Website of MDNA is: https://www.medicenna.com

How do I contact MDNA?

MDNA could be contacted at phone 416 648 5555 and can also be accessed through its website. MDNA operates from 2 Bloor Street West, Toronto, ON M4W 3E2, Canada.

How many shares of MDNA are traded daily?

MDNA stock volume for the day was 1.26M shares. The average number of MDNA shares traded daily for last 3 months was 1.26M.

What is the market cap of MDNA currently?

The market value of MDNA currently stands at $0.00 with its latest stock price at $0.16 and 0 of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	16
Beta	0.77
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	March
Sector	Healthcare
Industry	Biotechnology

MDNA Company Profile and Key Details

Medicenna Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics